Drug Approval | December 12, 2023
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Decision on EU marketing authorisation expected for momelotinib by early 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Subscribe To Our Newsletter & Stay Updated
